FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlight the comprehensive safety evaluation of Bremelanotide and its implications for clinical practice in treating hypoactive sexual desire disorder.
研究ライブラリに戻る
Bremelanotide

Highlight the comprehensive safety evaluation of Bremelanotide and its implications for clinical practice in treating hypoactive sexual desire disorder.

May 17, 2026
Share

元の論文

Safety Profile of Bremelanotide Across the Clinical Development Program.

Clayton Anita H et al.Journal of women's health (2002)2022
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Bremelanotide: A Comprehensive Safety Review for Treating Hypoactive Sexual Desire Disorder

Published: May 17, 2026 | Source: Journal of women's health (2002) (2022) | Category: Bremelanotide

Overview

A recent study published in the Journal of Women’s Health provides a detailed safety profile of Bremelanotide, a peptide therapy used to treat hypoactive sexual desire disorder (HSDD). The research highlights that Bremelanotide is generally well-tolerated with manageable side effects, offering valuable insights for both clinicians and patients considering this treatment option.

Study Background

Hypoactive Sexual Desire Disorder affects many women, often leading to significant distress in their personal relationships. While there are various treatments available, the safety profile of these therapies remains a critical concern. Bremelanotide, a melanocortin receptor agonist, has shown promise in clinical trials for treating HSDD. However, understanding its long-term safety and side effects is essential before it can be widely adopted.

What the Research Found

The study evaluated the safety data from multiple phases of Bremelanotide's clinical development program. Key findings include:

  • General Tolerance: The majority of participants reported that Bremelanotide was well-tolerated, with no severe adverse events linked to its use.
  • Side Effects Profile: Common side effects included nausea and headache, which were generally mild and transient.
  • No Serious Safety Concerns: There were no reports of serious safety issues or long-term complications associated with the drug.

What This Means for Peptide Users

For patients considering Bremelanotide as a treatment option for HSDD, this study provides reassurance regarding its overall safety. Clinicians can now feel more confident in recommending it based on the comprehensive data showing manageable side effects and no serious adverse events. However, individual patient responses may vary, so personalized consultations are crucial.

Limitations and Caveats

While the findings are encouraging, several limitations must be acknowledged:

  • Specific Inclusion Criteria: The study's participants were carefully selected, which limits its generalizability to a broader population.
  • Potential Biases: As with any clinical trial, there may be biases that affect the interpretation of results. For instance, patients who experience severe side effects might drop out early, skewing the data towards more positive outcomes.

How This Compares to Previous Research

This study builds on earlier research by providing a broader and more comprehensive safety evaluation across multiple phases of clinical development. Prior studies have also noted Bremelanotide's efficacy in treating HSDD but often lacked detailed long-term safety assessments. The current paper fills this gap, offering clinicians and patients a clearer picture of the drug’s risks versus benefits.

Our Analysis

At PeptideVault, we view this study as an important contribution to understanding Bremelanotide's safety profile. While it confirms the drug's efficacy and overall safety, the limitations highlight the need for ongoing research to ensure its suitability across diverse patient populations. The comprehensive nature of the data collected adds significant value to existing literature but should be interpreted with caution due to potential biases.

Key Takeaways

  • Well-Tolerated: Bremelanotide is generally well-tolerated by patients, with common side effects being mild and transient.
  • No Severe Adverse Events: The study did not report any serious safety concerns or long-term complications associated with the drug.
  • Further Research Needed: While promising, additional studies are required to confirm these findings in a broader patient population.

Original Source

Citation: Clayton Anita H, Kingsberg Sheryl A, Portman David et al. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program.. Journal of women's health (2002). DOI: 10.1089/jwh.2021.0191

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。